Free Trial
NASDAQ:SKYE

Skye Bioscience (SKYE) Stock Price, News & Analysis

Skye Bioscience logo
$4.58 +0.41 (+9.71%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$4.58 0.00 (0.00%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Skye Bioscience Stock (NASDAQ:SKYE)

Key Stats

Today's Range
$4.06
$4.65
50-Day Range
$1.98
$4.58
52-Week Range
$1.14
$7.47
Volume
947,978 shs
Average Volume
498,649 shs
Market Capitalization
$141.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60
Consensus Rating
Buy

Company Overview

Skye Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

SKYE MarketRank™: 

Skye Bioscience scored higher than 45% of companies evaluated by MarketBeat, and ranked 522nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Skye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Skye Bioscience has only been the subject of 2 research reports in the past 90 days.

  • Read more about Skye Bioscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Skye Bioscience are expected to decrease in the coming year, from ($1.04) to ($1.18) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Skye Bioscience is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Skye Bioscience is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Skye Bioscience has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    15.79% of the float of Skye Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Skye Bioscience has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Skye Bioscience has recently decreased by 9.32%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Skye Bioscience does not currently pay a dividend.

  • Dividend Growth

    Skye Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.79% of the float of Skye Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Skye Bioscience has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Skye Bioscience has recently decreased by 9.32%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Skye Bioscience has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Skye Bioscience this week, compared to 3 articles on an average week.
  • Search Interest

    17 people have searched for SKYE on MarketBeat in the last 30 days. This is an increase of 467% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Skye Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.50% of the stock of Skye Bioscience is held by insiders.

  • Percentage Held by Institutions

    Only 21.09% of the stock of Skye Bioscience is held by institutions.

  • Read more about Skye Bioscience's insider trading history.
Receive SKYE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SKYE Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

SKYE Stock Analysis - Frequently Asked Questions

Skye Bioscience's stock was trading at $2.83 at the beginning of the year. Since then, SKYE shares have increased by 61.7% and is now trading at $4.5750.

Skye Bioscience, Inc. (NASDAQ:SKYE) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.03.
Read the conference call transcript
.

Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/08/2025
Today
7/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SKYE
Previous Symbol
NASDAQ:SKYE
Fax
N/A
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.60
High Stock Price Target
$20.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+262.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.57 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.25 per share
Price / Book
2.03

Miscellaneous

Free Float
29,581,000
Market Cap
$141.73 million
Optionable
Optionable
Beta
1.95
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:SKYE) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners